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Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited disorder with 
variable expressivity, resulting in asymmetric septal hypertrophy and left ventricular 
outflow tract obstruction (LVOTO). Symptoms are similar to those of aortic stenosis 
and are due to LV diastolic dysfunction and myocardial ischemia in the absence of 
epicardial coronary narrowing. Goals of treatment include symptomatic control, reso-
lution of hemodynamic abnormalities and their sequelae, reduction of sudden cardiac 
death risk and screening of family members. Left ventricular outflow tract obstruction 
at rest is a predictor of severe symptoms, heart failure, and death. The majority of 
patients are managed medically, predominantly with b-blockers and calcium channel 
blockade. Disopyramide, a negative inotrope, can be used in cases with persistently 
high resting gradients. To prevent sudden cardiac death, implantable cardioverter-
defibrillators are used aggressively [1]. 
Surgical treatment has been limited to patients with refractory symptoms and high 
resting gradients. Results of surgical intervention are well documented, with 5% of 
patients being asymptomatic with accompanying dramatic reduction in outflow tract 
gradient. Transcoronary ablation of septal hypertrophy with alcohol – TASH procedure 
- is a newer percutaneous technique. It is designed to ablate hypertrophied cardiac 
septal muscle through localized infarction, but its efficacy compared with that of 
surgical myectomy is uncertain. Surgery is not indicated in the absence of significant 
left ventricular outflow tract obstruction. Only those patients with symptoms refrac-
tory to medication and obstruction either at rest or with provocation are generally 
referred for surgery [2].
Several techniques for relief of obstruction in hypertrophic obstructive car-
diomyopathy (HOCM) have been described ever since Cleland in 158 started with 
transaortic myotomy, a procedure known better as Bigelow technique. Septal myectomy 
rather than simple myotomy was introduced by Morrow in 161 and advanced over 
the years to the standard operation known as Morrow procedure. It was based on the 
assumption that the asymmetric septal hypertrophy was solely responsible for the left 
ventricular outflow tract obstruction [3].
Surgery for obstructive HCM has evolved over the past four decades, from ven-
tricular septal myotomy (i.e., without muscular resection), to the classic Morrow my-
ectomy. More recently, an extended and more extensive myectomy (up to about 7 cm 
long compared with 3 cm for the standard Morrow resection), combined with repair 
of mitral valve and submitral abnormalities, is practiced by some surgeons. Septal 
myectomy is performed through an aortotomy. A rectangular trough is created by 
first making two parallel longitudinal incisions in the basal septum near the nadir of 
the right coronary aortic cusp (RCC); septum beneath the commissure of the RCC 
and LCC. Incisions are extended distally and then connected transversely proximally 
below the aortic valve and distally just beyond the level of mitral-septal contact and 
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subaortic obstruction (with standard Morrow myectomy) or 
to mid-ventricular level at the base of papillary muscles (with 
extended myectomy), yielding 3 to 12 grams of septal muscle. 
It has been prudent practice to perform myectomy under 
intraoperative transesophageal echocardiographic guidance 
to directly monitor the efficacy of the resection (to identify 
the level of obstruction and distribution of septal hypertrophy) 
and allow for possible surgical revision. Mitral valve repair, in 
addition to myectomy, may be most appropriate for selected 
patients with severe mitral regurgitation caused by primary 
valvular disease (e.g., myxomatous, rheumatic or ruptured 
chordae). Occasionally, if intrinsic mitral valve disease is of 
sufficient severity to preclude repair, or the proximal septum is 
only mildly thickened and the risks for either septal perforation 
(by excessive muscular resection) or residual post-operative 
obstruction (by inadequate resection) are increased, then 
replacement with a low-profile mitral prosthesis without myec-
tomy may be prudent. Mitral valve replacement is, however, not 
routinely recommended as a primary treatment for obstruc-
tion, because of the potential postoperative complications 
related to durability, thromboembolism, and anticoagulation 
[1]. As an alternative to the transaortic approach, transatrial 
and transmitral myectomy has been attempted [4].
Occasionally, greatly elongated and flexible mitral leaflets 
will contribute substantially to the generation of mitral septal 
contact. In such selected cases, mitral valve plication combined 
with myectomy has been performed to restrict mitral valve mo-
tion and allow for more complete relief of subaortic obstruc-
tion and mitral regurgitation. Septal myectomy also offers an 
opportunity to repair associated major cardiac lesions such as 
atherosclerotic obstructive coronary artery disease or forms 
of fixed aortic stenosis, or surgically treat atrial fibrillation 
with the MAZE procedure.
Either alcohol ablation or myectomy offers substantial 
clinical improvement for patients with hypertrophic obstruc-
tive cardiomyopathy. Hemodynamic resolution of the ob-
struction and its sequelae is more complete with myectomy. 
Residual lesions after alcohol ablation might affect longer-
term outcomes.
Septal myectomy is a safe, reliable, and durable method 
of eliminating LVOT obstruction in HOCM [5]. It improves 
functional status, reduces mitral regurgitation and normal-
izes life expectancy. It is the benchmark for ablative therapies 
and is our preferred method for treating this complex and 
fascinating disease. Earlier reports mentioned a mortality 
rate of 4%-6% [6,7], more recent studies report mortality 
rates of less than 2% [5,8]. The surgical results are much 
improved due to better anesthesia, myocardial protection 
during cardio-pulmonary bypass, and the use of intra-op-
erative transesophageal echocardiography []. The latter 
permits a thorough evaluation of the surgical result upon the 
interventricular septum and, if required, the mitral valve, 
before the patient leaves the operating room. Complications 
of surgical myectomy include ventricular septal defect due 
to excessive removal of cardiac muscle, aortic regurgitation 
due to the transaortic approach and LBBB or complete heart 
block requiring a permanent pacemaker [2,10,11]. Alcohol 
ablation creates a strategically placed iatrogenic myocardial 
infarction (i.e., a scar). Currently published data suggest that 
procedural success is in the range of 75% to 80%, and among 
those successes, symptomatic improvement in the short-term 
and intermediate term is comparable with a myectomy [12]. 
However, despite the “less invasive” nature of this technique, 
the procedure-related morbidity and mortality are not lower 
than standard septal myectomy (SSM), and in some series they 
are higher. Importantly, there are no data indicating improved 
late survival after alcohol septal infarction. From a clinical 
investigation standpoint, it will be difficult for any procedure 
to show incremental benefit on the robust morbidity, mortality, 
hemodynamic, symptomatic, and survival benefits provided by 
SSM. Finally, among centers with substantial focus on HCM 
in which both the SSM and septal ablation are performed, the 
SSM myectomy is the preferred and proven therapy, whereas 
septal ablation is considered an alternative approach if surgical 
risk or other circumstances render surgery less attractive. A 
separate, but important consideration is risk of sudden death 
related to arrhythmia; although postoperative rates of sud-
den death are very low, risk is not zero, and patients should 
be evaluated longitudinally regarding the need for medical 
treatment or ICD therapy, or both [12-1].
r E f E r E N c E s
 1. Swistel DG, DeRose JJ, Sherid MV. Management of patients 
with complex hypertrophic cardiomyopathy: Resection / Plica-
tion / Release. Oper Tech Thorac Cardiovasc Surg 2004;:261–
67.
 2. Talreja DR, Nishimura RA, Edwards WD, et al. Alcohol septal 
ablation versus surgical septal myectomy: comparison of effects 
on atrioventricular conduction tissue. J Am Coll Cardiol 2004; 
44:232. 
 3. Dearani JA, Danielson GK. Septal myectomy for obstructive 
hypertrophic cardiomyopathy. Oper Tech Thorac Cardiovasc 
Surg 2004;:278 –2.
 4. Matsuda H. Transatrial and transmitral myectomy for hypertro-
phic obstructive cardiomyopathy of the left ventricle. Oper Tech 
Thorac Cardiovasc Surg 2004;:304–0.
 5.  Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of 
surgical septal myectomy on survival in patients with obstructive 
hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470–
6.
 6. Mohr R, Schaff HV, Danielson GK, et al. The outcome of surgi-
cal treatment of hypertrophic cardiomyopathy. Experience over 
15 years. J Thorac Cardiovasc Surg 18; 7:666.
 7. Brunner-La Schonbeck MH, Rocca HP, Vogt PR, et al. Long-
term follow-up in hypertrophic obstructive cardiomyopathy af-
ter septal myectomy. Ann Thorac Surg 18; 65:1207.
SURGERY FOR HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
177
 8. Woo A, Williams WG, Choi R, et al. Clinical and echocardio-
graphic determinants of long-term survival after surgical myec-
tomy in obstructive hypertrophic cardiomyopathy. Circulation 
2005; 111:2033.
 . Marwick TH, Steward WJ, Lever HM, et al. Benefits of intraop-
erative echocardiography in the surgical management of hyper-
trophic cardiomyopathy. J Am Coll Cardiol 12; 20:1066.
 10. Siegman IL, Maron BC, Permut LC, et al. Results of operation 
for coexistent obstructive hypertrophic cardiomyopathy and 
coronary artery disease. J Am Coll Cardiol 18; 13:1527.
 11. Brown PS, Roberts CS, McIntosh CL, et al. Aortic regurgitation 
after left ventricular myotomy and myectomy. Ann Thorac Surg 
11; 51:585
 12. Smedira NG, Lytle BW, Lever HM, et al. Current effectiveness 
and risks of isolated septal myectomy for hypertrophic obstruc-
tive cardiomyopathy. Ann Thorac Surg 2008;85:127–34.
 13. Maron BJ, Dearani JA, Ommen SR, et al. The case for surgery 
in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 
2004;44:2044 –53.
 14. Hess OM, Sigwart U. New treatment strategies for hypertrophic 
obstructive cardiomyopathy: alcohol ablation of the septum: the 
new gold standard? J Am Coll Cardiol 2004;44: 2054–5.
 15. Watkins H, McKenna WJ. The prognostic impact of septal my-
ectomy in obstructive hypertrophic cardiomyopathy. J Am Coll 
Cardiol 2005;46:477–.
 16. Salberg L. Treating hypertrophic cardiomyopathy: two views. J 
Am Coll Cardiol 2005;46:2147.
 17. Ralph-Edwards A, Woo A, McCrindle BW, et al. Hypertrophic 
obstructive cardiomyopathy: comparison of outcomes after my-
ectomy or alcohol ablation adjusted by propensity score. J Tho-
rac Cardiovasc Surg 2005;12:351– 8.
 18. Yacoub M, Onuzo O, Riedel B, Radley-Smith R. Mobiliza-
tion of the left and right fibrous trigones for relief of severe 
left ventricular outflow obstruction. J Thorac Cardiovasc Surg 
1;117:126 –33.
 1. Qin JX, Shiota T, Lever HM, et al. Conduction system abnor-
malities in patients with obstructive hypertrophic cardiomy-
opathy following septal reduction interventions. Am J Cardiol 
2004;3:171–5.
